Philips and Diagnostics Development win European Union 'Horizon Prize - Better Use of Antibiotics'

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in HealthTech, and Diagnostics Development, a P&M Venge company spin-off from Uppsala University (Sweden), have demonstrated a proof-of-concept for the rapid and reliable detection of bacterial infection. The test is based on Philips' Minicare I-20 handheld diagnostics platform and detects the human neutrophil lipocalin (HNL) biomarker in a single 'finger-prick' drop of blood. In recognition of the test's ability to distinguish between acute bacterial and viral infections, and thereby mitigate the unnecessary use of antibiotics, the two companies were awarded the European Union 'Horizon Prize - Better Use of Antibiotics' during a special award ceremony on the evening of February 6, 2017.

Antimicrobial agents - such as antibiotics - have dramatically reduced the number of deaths from infectious diseases since their introduction 70 years ago. However, through their overuse and misuse, many micro-organisms have become resistant to them. It is estimated that each year this growing antimicrobial resistance (AMR) causes around 25,000 deaths and accounts for over EUR 1.5 billion in healthcare costs and productivity losses in Europe alone, making it one of the greatest challenges facing society today. To boost development and bring new and innovative players to AMR research, the EU issued a prize for the individual or team that most effectively meets the following challenge: "to develop a rapid test that will allow healthcare providers to distinguish at the point of care between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without antibiotics".

"This prize is a great recognition of how collaboration can lead to innovative diagnostic solutions that improve patient care," said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips. "The HNL program for detection of bacterial infections perfectly fits with our 'open platform' strategy of bringing innovative biomarker content onto the Minicare I-20 platform in order to offer healthcare professionals a panel of relevant tests for acute settings. Activities are ongoing to further develop the HNL test for eventual implementation in routine clinical practice.

"In various studies, HNL has demonstrated superior performance compared to biomarkers currently used to diagnose bacterial infection," said Per Venge, CEO of P&M Venge AB. "I am therefore very excited that we have been able to successfully demonstrate the detection of HNL on the Minicare I-20 using blood samples from patients with upper respiratory tract infections in the Uppsala University hospital, where within a few minutes patients with a bacterial infection could clearly be distinguished from those with viral infections or other conditions."

Based on Philips' proprietary biosensor technology, the Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single 'finger-prick' blood sample, and display the results on a handheld analyzer within minutes. Philips already has CE marking for its Minicare I-20 based cardiac troponin I (cTnI) blood test for the rapid point-of-care diagnosis of heart attack, and it is currently developing further tests for acute care settings.

Minicare I-20 is simple and easy to use by non-laboratory staff. The analyzer's built-in connectivity allows direct transfer of the data to laboratory and hospital information systems to update patient files, while integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident on-the-spot decision making.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

Most Popular Now

Which Self-Help Websites Actually Improv…

From depression to weight loss, insomnia to cutting back on alcohol or cigarettes, the Internet teems with sites that promise to help people improve their health. Which of these really...

Read more

AbedGraham and Highland Marketing Partne…

Global efforts to enhance clinical engagement and accelerate the impact of digital technology in improving patient care, will be boosted by a new bilateral relationship between two organisations dedicated to...

Read more

The Grants4Apps® Accelerator Berlin 2017

The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from September until November. The program offers mentoring...

Read more

Highland Marketing Recruits Strategy and…

PR and marketing agency Highland Marketing has appointed Lyn Whitfield to the new post of strategy and content director. Whitfield is a journalist by background, who has specialised in writing...

Read more

Philips and PathAI Team Up to Improve Br…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and PathAI, a company that develops artificial intelligence technology for pathology, are collaborating with the aim to develop...

Read more

PatientsLikeMe and Shire Pharmaceuticals…

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

Read more

Biased Bots: Human Prejudices Sneak into…

In debates over the future of artificial intelligence, many experts think of the new systems as coldly logical and objectively rational. But in a new study, researchers have demonstrated how...

Read more

Philips High-Risk Pregnancy Toolkit is …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included as a "Developing-World" and "Health" categories finalist in the 'Fast Company - World Changing Ideas...

Read more

Allscripts Announces dbMotionTM Solution…

Allscripts (NASDAQ:MDRX) announced today that its Community interoperability platform, dbMotion Solution, is now available through the cloud via Microsoft Azure. The cloud-based solution offers the same capabilities as the on-premise...

Read more

Health 2.0 Europe 2017

3 - 5 May 2017, Barcelona, Spain. The 8th edition of Health 2.0 Europe will take place in Barcelona in a new location: Fira Montjuic, Plaza España. Health 2.0 Europe will...

Read more

FDA Allows Marketing of First Direct-to-…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC)...

Read more

Public Funding Essential for Advances in…

In the budget President Trump recently submitted to Congress, he asked for a reduction in the 2018 funding of the U.S. National Institutes of Health (NIH) of almost 20 percent...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined